Detalhe da pesquisa
1.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728378
2.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
3.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood
; 141(19): 2359-2371, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626250
4.
Chromothripsis as a pathogenic driver of multiple myeloma.
Semin Cell Dev Biol
; 123: 115-123, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958284
5.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Am J Hematol
; 98(3): 421-431, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588413
6.
Weight-Based Enoxaparin for Venous Thromboembolism in Obesity Gives Similar Anti-Xa Levels to Patients <100 kg, with No Increase in Major Bleeding.
Semin Thromb Hemost
; 45(1): 94-99, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630208
7.
Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma.
Clin Cancer Res
; 30(3): 575-585, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939148
8.
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
Clin Cancer Res
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652812
9.
Targeting the ribosome to treat multiple myeloma.
Mol Ther Oncol
; 32(1): 200771, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38596309
10.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Blood Adv
; 8(1): 236-247, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772981
11.
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
Res Sq
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38405866
12.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Blood Adv
; 8(7): 1600-1611, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37878808
13.
Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
Blood Adv
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621239
14.
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Blood Adv
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598713
15.
Genomic Classification and Individualized Prognosis in Multiple Myeloma.
J Clin Oncol
; 42(11): 1229-1240, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194610
16.
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival.
Blood Cancer J
; 13(1): 175, 2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030619
17.
Impact of rare structural variant events in newly diagnosed multiple myeloma.
bioRxiv
; 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36711679
18.
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.
Blood Adv
; 7(6): 971-981, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332058
19.
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.
Res Sq
; 2023 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865246
20.
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Blood Cancer J
; 13(1): 112, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491332